Bulk Inquiry
MDV 3100
- Enzalutamide
- Soluble in DMSO
- MF: C21H16F4N4O2S
- MW: 464.44
Description
MDV 3100 is a potent, orally active androgen receptor antagonist that inhibits androgen-dependent AR signaling.
MDV 3100 blocks multiple steps of androgen receptor activation, including ligand-driven signaling and downstream transcriptional responses. It is a benchmark compound for studying advanced prostate cancer biology, antiandrogen resistance and nuclear receptor pharmacology.
Key Features
- Potent androgen receptor antagonist
- Blocks androgen-dependent AR transcriptional signaling
- Relevant to advanced prostate cancer research
- Useful for studying antiandrogen resistance mechanisms
Applications
- Androgen receptor pharmacology
- Prostate cancer model studies
- AR transcriptional activity assays
- Antiandrogen resistance and combination research
More Information
| Parent CAS No. | 915087-33-1 |
|---|---|
| Chemical Name | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide |
| SMILES | C1(=O)N(C2C=C(C(F)(F)F)C(C#N)=CC=2)C(=S)N(C2C=CC(C(NC)=O)=C(F)C=2)C1(C)C |
| MFCD | MFCD14155804 |
| InChi | InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30) |
| InChiKey | WXCXUHSOUPDCQV-UHFFFAOYSA-N |
| CID | 15951529 |
| Short Description | AR antagonist |
References
- C Tran et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324 (5928), 787-790.
- C Harrison. Anticancer drugs: New approaches to anti-androgen activities. Nature Reviews Drug Discovery 2009, 8, 452-453.
- CJ Hoimes and WK Kelley. Redefining hormone resistance in prostate cancer. Ther. Adv. Med. Oncol. 2010, 2(2), 107–123.
- G Di Lorenzo et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70(8), 983-1000.
- N Sharifi. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Exp. Opin. Invest. Drugs 2010, 19(7), 837-846.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1357 | SD 169 |
From $66.00 |
| 1358 | BIRB 796 |
From $71.50 |
| 1363 | SB 203580 |
From $104.50 |
| 1364 | SB 202190 |
From $104.50 |
| 1365 | PD169316 |
From $104.50 |
| 1532 | RD 162 |
From $137.50 |
| 1680 | RU 58841 |
From $88.00 |
| 1873 | Abiraterone |
From $99.00 |
| 1874 | Abiraterone acetate |
From $99.00 |
| 1979 | ARN 509 |
From $104.50 |
| 2124 | TAK 700 |
From $115.50 |
| 3249 | Nilutamide |
From $66.00 |
| 3313 | Bicalutamide |
From $55.00 |
| 3322 | Dehydroepiandrosterone |
From $66.00 |
| 3883 | Cyproterone acetate |
From $66.00 |
| 4248 | SC912 |
From $143.00 |
| 4328 | Hydroxyflutamide |
From $132.00 |
